Published in conjunction with the 2015 ASCO Annual Meeting
Targeted therapies may increase survival in metastatic NSCLC. Thus, genomic profiling is recommended to aid treatment selection. Utilization & impact of testing in community (non-research) settings is underexplored.
Authors: Martin Gutierrez, Harry D. Harper, Bohdan E. Halibey, Vincent A. Miller, Jerry Conway, Mark Oldroyd, Kelly Choi, Eric V Schultz, Andrew Pecora, Stuart L. Goldberg; Regional Cancer Care Associates, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ; Regional Cancer Care Associates - Sparta Division, Sparta, NJ; Foundation Medicine, Inc., Cambridge, MA; Cancer Outcomes Tracking and Analysis, New York, NY